<DOC>
	<DOCNO>NCT01221688</DOCNO>
	<brief_summary>GANEA 2 new trial base patient treat large breast tumor proven axillary involve node . Patients enrol trial first axillary sonography fine needle punction case suspect node NAC . This primary evaluation allow determine two group patient : group 1 : patient proven involve axillary node group 2 , patient without proven axillary involve node . Patients group 1 , study group , undergo SLNB complete level I-II axillary lymphadenectomy . Patients group 2 undergo SLNB complete axillary level I-II lymphadenectomy case detection failure involve SLN SLNB alone others case . Patients last group follow 5 year order evaluate risk axillary relapse without lymphadenectomy .</brief_summary>
	<brief_title>Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy Large Operable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>T2T3 operable infiltrate breast carcinoma No allergy Patent Blue Preoperative diagnosis unilateral infiltrate breast carcinoma . Patient plan treat NAC . Informed consent . Surgery available 4 6 week last chemotherapy course ( radical conservative surgery ) pT4d ( inflammatory breast cancer ) Locally advanced metastatic breast cancer Any previous chemotherapy contralateral breast cancer . Breast cancer local relapse Previous surgical removal breast Cancer . Inadequate biopsy pathological analysis . Dementia alter mental disorder Pregnant woman breast feed without efficacious contraceptive method . Contraindication NAC NAC interrupt due progressive disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Sentinel lymph node biopsy ( SLNB )</keyword>
	<keyword>large operable breast cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>patient large operable breast cancer neoadjuvant chemotherapy ( NAC )</keyword>
</DOC>